Abstract
The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Protein & Peptide Letters
Title:Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha
Volume: 20 Issue: 4
Author(s): Xiaoming Lu, Chao Cheng, Guobin Wang, Xiaogang Shu, Jingwei Ma and Qiang Tong
Affiliation:
Keywords: Superantigens, MG7-scFv/SEB, tumor necrosis factor, combination, gastric cancer, fusion protein, cytokine, gastric tumor, combined therapy, cancer therapy
Abstract: The fusion protein MG7-scFv/SEB has shown anti-tumor activity on gastric cancer in vitro and in vivo. Tumor necrosis factor-alpha (TNF-α) is a cytokine exerting anti-tumor effectiveness in various models and modes of applications. In this study, we explored the combination effects of MG7-scFv/SEB and TNF-α in experimental gastric cancer. Both MG7-scFv/SEB and TNF-α could effectively result in a significant inhibition of tumor growth in our experimental models when administered alone. What’s more, MG7-scFv/SEB synergized with TNF-α in further reducing the growth of gastric tumors in gastric-tumor-bearing rats as compared to mono therapy. Additionally, the survival rate of gastric-tumorbearing rats administrated with combined therapy was significantly higher than that of rats treated with MG7-scFv/SEB or TNF-α. These results indicate that combined therapy with MG7-scFv/SEB and TNF-α is a promising strategy for human cancer therapy.
Export Options
About this article
Cite this article as:
Lu Xiaoming, Cheng Chao, Wang Guobin, Shu Xiaogang, Ma Jingwei and Tong Qiang, Synergistic Enhancement of Cancer Therapy Using a Combination of Fusion Protein MG7-scFv/SEB and Tumor Necrosis Factor Alpha, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040011
DOI https://dx.doi.org/10.2174/0929866511320040011 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews Current and Emerging Strategies in Bladder Cancer
Anti-Cancer Agents in Medicinal Chemistry Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targeting of TRPV1 by Resiniferatoxin, from Preclinical Studies to Clinical Trials
Current Topics in Medicinal Chemistry Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Current Pharmaceutical Design Synthetic Methods for the Preparation of Triazepandiones and Review of their Applications
Current Organic Chemistry Synthesis of Bacteriochlorins and Their Potential Utility in Photodynamic Therapy (PDT)
Current Organic Chemistry Genitourinary Tract Tumors in Children: An Update
Current Pediatric Reviews RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Innovations and Improvements in Pharmacokinetic Models Based on Physiology
Current Drug Delivery Crotamine, a Small Basic Polypeptide Myotoxin from Rattlesnake Venom with Cell-Penetrating Properties
Current Pharmaceutical Design HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Three-Dimensional Tissue Models for Drug Discovery and Toxicology
Recent Patents on Biotechnology Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Natural Products: Potential for Developing Phellodendron amurense Bark Extract for Prostate Cancer Management
Mini-Reviews in Medicinal Chemistry Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry DNA Repair Pathways and Human Metastatic Malignant Melanoma
Current Molecular Medicine Radiopharmaceutical Tracking of Particles Injected into Tumors: A Model to Study Clearance Kinetics
Current Drug Delivery